VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,710,453 | +6.3% | 896,635 | +4.1% | 0.01% | +12.5% |
| Q2 2023 | $42,995,393 | +71.7% | 860,941 | +28.8% | 0.01% | +60.0% |
| Q1 2023 | $25,047,959 | -20.8% | 668,302 | +1.4% | 0.01% | -28.6% |
| Q4 2022 | $31,614,921 | +172.2% | 659,331 | +36.3% | 0.01% | +133.3% |
| Q3 2022 | $11,613,000 | +14.9% | 483,892 | +4.2% | 0.00% | +50.0% |
| Q2 2022 | $10,104,000 | +9.5% | 464,337 | +21.5% | 0.00% | 0.0% |
| Q1 2022 | $9,228,000 | +4.4% | 382,125 | +2.9% | 0.00% | +100.0% |
| Q4 2021 | $8,838,000 | -7.1% | 371,462 | -1.0% | 0.00% | -50.0% |
| Q3 2021 | $9,517,000 | +15.6% | 375,107 | +2.6% | 0.00% | +100.0% |
| Q2 2021 | $8,230,000 | +43.2% | 365,652 | +25.7% | 0.00% | 0.0% |
| Q1 2021 | $5,746,000 | -3.1% | 290,958 | +30.4% | 0.00% | 0.0% |
| Q4 2020 | $5,929,000 | -44.0% | 223,120 | +4.0% | 0.00% | -50.0% |
| Q3 2020 | $10,593,000 | – | 214,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |